Recursion Pharmaceuticals' stock has been volatile, and is soaring today on news the FDA is planning on phasing out some animal testing, replacing it with AI. The company's Q4 FY24 earnings showed ...

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...

In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes through) become one company, combining Recursion’s expertise in biology with Exscientia’s focus on chemistry.

Recursion Pharmaceuticals' stock jumped after the FDA announced plans to replace the use of animals in drug testing. Recursion is a leader in AI-powered drug discovery and development. It remains ...

Recursion Pharmaceuticals saw its stock price increase by 12% over the past week. This movement could be associated with several recent developments. The company announced a significant follow-on ...

At close: April 11 at 4:00:00 PM EDT ...

Her expertise is in personal finance and investing, and real estate. Morsa Images / Getty Images Sequence risk is the danger that the timing of withdrawals from a retirement account will have a ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...